Cephalon Provigil Reformulation Will Be Filed With FDA By Year-End

Cephalon's $100 mil. in new financing from a preferred stock offering finalized on Aug. 13 will help tide the company over while it develops new indications for its lead drug, wakefulness agent Provigil.